Title |
Insights into the immune responses of SARS-CoV-2 in relation to COVID-19 vaccines |
Author |
Heedo Park, Mee Sook Park, Jong Hyeon Seok, Jaehwan You, Jineui Kim, Jeonghun Kim, and Man-Seong Park* |
Address |
Department of Microbiology, Institute for Viral Diseases, Chung Mong-Koo Vaccine Innovation Center, College of Medicine, Korea University, Seoul 02841, Republic of Korea |
Bibliography |
Journal of Microbiology, 60(3),308-320, 2022,
|
DOI |
10.1007/s12275-022-1598-x
|
Key Words |
COVID-19, SARS-CoV-2, immune response,
mRNA-1273, BNT162b2, ChAdOx1 nCoV-19, Ad26.COV2.S,
vaccine |
Abstract |
The three types of approved coronavirus disease 2019 (COVID-
19) vaccines that have been emergency-use listed (EUL) by
the World Health Organization are mRNA vaccines, adenovirus-
vectored vaccines, and inactivated vaccines. Canonical
vaccine developments usually take years or decades to be completed
to commercialization; however, the EUL vaccines being
used in the current situation comprise several COVID-
19 vaccine candidates applied in studies and clinical settings
across the world. The extraordinary circumstances of the
COVID-19 pandemic have necessitated the emergency authorization
of these EUL vaccines, which have been rapidly
developed. Although the benefits of the EUL vaccines outweigh
their adverse effects, there have been reports of rare but
fatal cases directly associated with COVID-19 vaccinations.
Thus, a reassessment of the immunological rationale underlying
EUL vaccines in relation to COVID-19 caused by SARSCOV-
2 virus infection is now required. In this review, we discuss
the manifestations of COVID-19, immunologically projected
effects of EUL vaccines, reported immune responses,
informed issues related to COVID-19 vaccination, and the
potential strategies for future vaccine use against antigenic
variants. |